Why Guardant Health (GH) Stock Is Down Today

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

GH Cover Image

What Happened?

Shares of diagnostics company Guardant Health (NASDAQ: GH) fell 4.1% in the afternoon session after Co-CEO AmirAli Talasaz sold 50,000 shares of company stock, a transaction valued at over $5 million. 

Large stock sales by top executives can sometimes worry investors, as they may suggest that leadership has concerns about the company's short-term valuation or future performance. This significant insider activity has drawn attention to the company's stock.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Guardant Health? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Guardant Health’s shares are very volatile and have had 26 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The biggest move we wrote about over the last year was 6 months ago when the stock dropped 8.8% on the news that the company announced the pricing of an upsized convertible senior notes offering and a public stock offering, raising concerns about dilution for existing shareholders. 

The company priced $350 million of convertible senior notes, an increase from the previously announced $300 million offering. Concurrently, Guardant Health priced a public offering of more than 3.3 million shares of its common stock at $90.00 per share. Such financial moves, while raising capital for the company, often lead to a drop in stock price. This is because the issuance of new shares and securities that can be converted into shares can dilute the ownership stake of current investors, making each existing share represent a smaller piece of the company.

Guardant Health is down 6.2% since the beginning of the year, and at $95.39 per share, it is trading 18.7% below its 52-week high of $117.28 from January 2026. Investors who bought $1,000 worth of Guardant Health’s shares 5 years ago would now be looking at only $846.76.

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  264.14
-3.08 (-1.15%)
AAPL  300.23
+2.02 (0.68%)
AMD  424.10
-25.60 (-5.69%)
BAC  49.77
-0.08 (-0.16%)
GOOG  393.32
-3.85 (-0.97%)
META  614.23
-4.20 (-0.68%)
MSFT  421.92
+12.49 (3.05%)
NVDA  225.32
-10.42 (-4.42%)
ORCL  192.95
-2.66 (-1.36%)
TSLA  422.24
-21.06 (-4.75%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.